Database→SNAP-8

Tier 3–4SkinAnti-agingPREMIUM

SNAP-8

SNAP-8 (Acetyl Octapeptide-3 / Acetyl Glutamyl Heptapeptide-1 / Ac-EEMQRRAD-NH2)

Cosmetic ingredient only. Regulated in the USA by FDA as a cosmetic, not a drug. No drug approval exists or has been sought. INCI name: Acetyl Octapeptide-3. Not WADA-listed. No compounding restrictions apply as it is not used as an injectable drug. Developed by Lipotec (now Lubrizol) and supplied commercially as a 0.05% aqueous solution.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

SNAP-8 (Acetyl Octapeptide-3) is a synthetic cosmetic octapeptide developed by Lipotec as an extended analog of Argireline, designed to more completely mimic the N-terminal domain of SNAP-25 and improve competitive inhibition of SNARE complex formation. The widely cited '63% wrinkle reduction in 28 days' claim comes from Lipotec's own technical data sheet, not a peer-reviewed publication. No standalone placebo-controlled RCT of topical SNAP-8 exists. The two published human studies are a confounded multi-ingredient microneedle patch trial (Shin 2024, n=24) and an open-label multi-peptide serum with no placebo arm (Draelos 2016, n=29). SNAP-8 has a mechanistically plausible design and clean safety record, but its evidence base is the weakest of any cosmetic peptide profiled in this series.

🔒

Full Profile: Premium Members Only

The complete SNAP-8 profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use